Improve Safety in Polymedication by Managing Drug-Drug-Gene Interactions

Informazioni relative al progetto

SafePolyMed

ID dell’accordo di sovvenzione: 101057639

DOI 10.3030/101057639

Data della firma CE 23 Maggio 2022

Data di avvio 1 Giugno 2022

Data di completamento 30 Novembre 2025

Finanziato da

• Health

Costo totale € 5 650 444,56

Contributo UE € 5 650 442,81

Coordinato da

UNIVERSITAT DES SAARLANDES
Germany

Risultati finali

Websites, patent fillings, videos etc. (2)

Public Project Website
Audio-visual material

Documents, reports (5)

Selection of clinically relevant compounds
English-Estonian dictionary
Content for the training curriculum for empowerment of patients in pharmacology and drug safety
Design and implementation of the SafePolyMed platform for the analysis of the retrospective data
Patient engagement Hub: setup of a priority setting network of different patient organisations

Pubblicazioni

Peer reviewed articles (1)

Genetic predictors of lifelong medication-use patterns in cardiometabolic diseases

Autori: Tuomo Kiiskinen, Pyry Helkkula, Kristi Krebs, Juha Karjalainen, Elmo Saarentaus, Nina Mars, Arto Lehisto, Wei Zhou, Mattia Cordioli, Sakari Jukarainen, Joel T. Rämö, Juha Mehtonen, Kumar Veerapen, Markus Räsänen, Sanni Ruotsalainen, Mutaamba Maasha, F
Pubblicato in: Nature Medicine, Numero 29, 2023, ISSN 1078-8956
Editore: Nature Medicine (Nat Med)
DOI: 10.1038/s41591-022-02122-5